EGFR and head and neck squamous cell carcinoma: The failure of erlotinib to improve tumor control in the animal studies [20] proves that this cell cycle arrest-dependent radiosensitization does not translate into improved tumor control and is therefore unlikely to contribute to a clinical effect of EGFR targeting in HNSCC patients.